Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Haolin Ni who wrote (243)	7/2/1998 7:40:00 PM
From: Robert Mayo	Read Replies (2) \| Respond to of 712

All: Spotted this on DJ wire: "FDA Says Cor Therapeutics' Letter On Integrilin Incomplete Dow Jones Newswires "WASHINGTON -- Less than a month after its new heart drug, Integrilin, hit the market, Cor Therapeutics Inc. (CORR) received notice from the U.S. Food and Drug Administration that it improperly marketed the product. "The FDA said that a letter the company sent to doctors and pharmacists announcing the new anti-clotting heart drug didn't properly warn about the drug's risks. "Ellen Martin, Cor Therapeutics' vice president for regulatory affairs, said the company has drafted a letter to reply to the FDA. The FDA's notice of violation letter requires the company respond on or before July 10. "Martin said full prescribing information, which explains the drug's risks, accompanied the letters Cor Therapeutics sent to health professionals. "However, the FDA said the letter itself wasn't balanced. "They thought the total safety information should have been included in the letter," Martin said. "Integrilin hit the market June 8 as a treatment for patients undergoing angioplasty and for those with unstable angina." ###### ###### ###### Bob